The research paper on Patanjali’s herbal formulation, Renogrit, has been recognized as one of the top 100 research papers of 2024 in the prestigious Scientific Reports journal, part of the Nature Portfolio publication. This achievement is a significant milestone in establishing the scientific credibility of Ayurveda on a global scale. Renogrit, a simple herbal formulation, has demonstrated its potential in combating severe diseases without adverse side effects. The research study found that Renogrit not only repairs kidney damage caused by the anti-cancer drug, cisplatin, but also alleviates oxidative stress on kidney cells.
The study, conducted by a team of scientists, used human renal proximal tubular cells and the Caenorhabditis elegans model to examine the protective effects of Renogrit. The results showed that the formulation regulated renal injury markers, reduced oxidative stress, improved mitochondrial function, and modulated key cell death pathways. Importantly, Renogrit did not interfere with the anti-cancer effects of cisplatin on cancer cells, making it a viable candidate for adjunctive therapy.
Acharya Balkrishna, a member of the research team, expressed his enthusiasm for the study, stating that it is a significant step in establishing the scientific credibility of Ayurveda globally. He believes that when ancient wisdom is tested on modern scientific parameters, it yields groundbreaking results. The success of Renogrit opens up new avenues for integrating Ayurvedic medicine with modern therapeutic approaches, enhancing patient outcomes and reinforcing the value of traditional medicine. With an Impact Factor of 3.8, Scientific Reports is one of the most highly respected and widely cited journals in the world, making this achievement a testament to the validity and potential of Ayurvedic medicine.